EGFR and metastatic colorectal cancer: Additionally, USD 604 million in annual savings would be realized if genetic tests limiting anti-epidermal growth factor receptor (EGFR) therapy to metastatic colorectal cancer patients with wild-type KRAS tumors are carried out [18].